Epilepsy | Treatment Algorithms: Claims Data Analysis | Generalized-Onset Seizures | US | 2024

Generalized-onset seizures (GOS) simultaneously affect both sides of the brain and rapidly engage bilaterally distributed networks. Nearly 40% of the diagnosed epilepsy population presents with generalized seizures. GOS patients require individualized treatment, and neurologists consider multiple factors when choosing treatment, such as the patient’s age, history, and seizure subtype. Based on national patient-level claims data, this report explores the use of key therapies in both newly diagnosed and recently treated patients; examines the line-of-therapy progression, including switching and adding patterns of various antiepileptic drugs; and assesses persistence and compliance with drug treatment, including by formulation.

Questions answered

• What shares do key therapies and brands garner by line of therapy in newly diagnosed GOS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed GOS patients?
• How has UCB’s Vimpat been integrated into the treatment algorithm, and what is its source of business?
• What percentage of GOS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of GOS patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.